Long term survival after lung transplantation: A single center experience.


Journal

Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809

Informations de publication

Date de publication:
Feb 2020
Historique:
pubmed: 8 8 2019
medline: 1 9 2020
entrez: 8 8 2019
Statut: ppublish

Résumé

There are approximately 2000 lung transplants performed across the United States annually. There is limited data to identify factors predictive of long-term survival. We evaluated 10-year survivors after lung transplant to determine predictors of long-term survival. Data were collected from the United Network for Organ Sharing registry database from a single institution. Inclusion criteria were: patients who received a lung transplant between 1989 and 2005. Descriptive statistics were calculated, and survival outcomes were analyzed using the Kaplan-Meier method. Three hundred sixty-one patients received a lung transplant between 1989 and 2005, and 77 patients survived at least 10 years (21%). Diagnoses at the time of transplant included: chronic obstructive pulmonary disease/emphysema 45 (58.4%), idiopathic pulmonary fibrosis 12 (15.6%), alpha 1 anti-trypsin deficiency 6 (7.8%), cystic fibrosis 4 (5.2%), primary pulmonary hypertension 2 (2.6%), and Eisenmenger's syndrome 1 (1.3%). Seventy-four recipients (96.10%) were Caucasian; 46 (59.74%) were female. Age at the time of transplant ranged from 19 to 67 years (mean 50.8; median 52). Forty-two patients (54.5%) were double lung recipients. Survival ranged from 10.0 to 21.9 years (mean 15.5y; median 15.48y). Forty-two (54.5%) subjects are currently alive; the most common causes of death included: chronic rejection (20%), and infection (17.14%). Ten-year survivors were significantly younger, weighed less, and had significantly shorter lengths of hospitalization after transplantation. Bilateral lung transplantation was a significant factor in prolonged survival. Survival also improved with institutional experience.

Sections du résumé

BACKGROUND BACKGROUND
There are approximately 2000 lung transplants performed across the United States annually. There is limited data to identify factors predictive of long-term survival.
OBJECTIVE OBJECTIVE
We evaluated 10-year survivors after lung transplant to determine predictors of long-term survival.
METHODS METHODS
Data were collected from the United Network for Organ Sharing registry database from a single institution. Inclusion criteria were: patients who received a lung transplant between 1989 and 2005. Descriptive statistics were calculated, and survival outcomes were analyzed using the Kaplan-Meier method.
RESULTS RESULTS
Three hundred sixty-one patients received a lung transplant between 1989 and 2005, and 77 patients survived at least 10 years (21%). Diagnoses at the time of transplant included: chronic obstructive pulmonary disease/emphysema 45 (58.4%), idiopathic pulmonary fibrosis 12 (15.6%), alpha 1 anti-trypsin deficiency 6 (7.8%), cystic fibrosis 4 (5.2%), primary pulmonary hypertension 2 (2.6%), and Eisenmenger's syndrome 1 (1.3%). Seventy-four recipients (96.10%) were Caucasian; 46 (59.74%) were female. Age at the time of transplant ranged from 19 to 67 years (mean 50.8; median 52). Forty-two patients (54.5%) were double lung recipients. Survival ranged from 10.0 to 21.9 years (mean 15.5y; median 15.48y). Forty-two (54.5%) subjects are currently alive; the most common causes of death included: chronic rejection (20%), and infection (17.14%).
CONCLUSIONS CONCLUSIONS
Ten-year survivors were significantly younger, weighed less, and had significantly shorter lengths of hospitalization after transplantation. Bilateral lung transplantation was a significant factor in prolonged survival. Survival also improved with institutional experience.

Identifiants

pubmed: 31389633
doi: 10.1111/jocs.14163
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

273-278

Subventions

Organisme : NIH HHS
ID : 1U54GM115428
Pays : United States

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

David Blitzer (D)

Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana.

Hannah Copeland (H)

Division of Cardiac Surgery, Department of Surgery, University of Mississippi Medical Center, Jackson, Mississippi.

David Roe (D)

Department of Medicine Pulmonary, Critical Care, Transplant Medicine, Indiana University School of Medicine, Methodist Hospital, Indianapolis, Indiana.

Chadi Hage (C)

Department of Medicine Pulmonary, Critical Care, Transplant Medicine, Indiana University School of Medicine, Methodist Hospital, Indianapolis, Indiana.

I-Wen Wang (IW)

Department of Cardiothoracic Transplant Surgery, Indiana University School of Medicine Methodist Hospital, Indianapolis, Indiana.

Michael Duncan (M)

Department of Medicine Pulmonary, Critical Care, Transplant Medicine, Indiana University School of Medicine, Methodist Hospital, Indianapolis, Indiana.

Joshua Manghelli (J)

Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana.

Danyel Gooch (D)

Department of Transplant Medicine, Indiana University Methodist Hospital, Indianapolis, Indiana.

Thomas Wozniak (T)

Department of Cardiothoracic Transplant Surgery, Indiana University School of Medicine Methodist Hospital, Indianapolis, Indiana.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH